Husam Younis - 20 Apr 2026 Form 4 Insider Report for Atrium Therapeutics, Inc. (RNA)

Reporting relationship: Chief Scientific Officer
Issuer ticker: RNA
Reported as of: 20 Apr 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 22 Apr 2026, 17:40:29 UTC
Prior SEC filing: 26 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Brendan Winslow, Attorney-in-Fact

Key filing fact

Husam Younis filed Form 4 for Atrium Therapeutics, Inc. (RNA) on 22 Apr 2026.

Key facts

This page summarizes Husam Younis's Form 4 filing for Atrium Therapeutics, Inc. (RNA).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 22 Apr 2026, 17:40.

Change

Previous filing in this sequence was filed on 26 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002107586 Primary reporting owner

Younis Husam

Relationship: Chief Scientific Officer
Address: C/O ATRIUM THERAPEUTICS, INC., 10578 SCIENCE CENTER DRIVE, SUITE 125, SAN DIEGO
Signature: /s/ Brendan Winslow, Attorney-in-Fact
Signature date: 22 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RNA transaction

Common Stock

Award

Transaction value
Shares: +30,000
Change %: +132%
Price: $0.000000^*
Shares after: 52,657
Date: 20 Apr 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RNA transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +60,000
Change %
Price: $0.000000^*
Shares after: 60,000
Date: 20 Apr 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 60,000
Exercise price: $14.30
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Twenty-five percent (25%) of the RSUs shall vest on March 20, 2027, with the remaining RSUs vesting in three (3) substantially equal yearly installments each year thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.

Footnote F2

Twenty-five percent (25%) of the shares underlying this option shall vest and become exercisable on March 20, 2027, with the remaining shares vesting in thirty-six (36) substantially equal monthly installments each month thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.